Sacuva Tablet 24 mg+26 mg is a fixed-dose combination of Sacubitril 24 mg and Valsartan 26 mg, formulated for the management of heart failure with reduced ejection fraction (HFrEF). This combination belongs to the class of angiotensin receptor-neprilysin inhibitors (ARNIs), offering dual action: Sacubitril inhibits neprilysin, increasing beneficial natriuretic peptides, while Valsartan blocks the angiotensin II receptor, reducing vasoconstriction and fluid retention.

Sacuva helps improve cardiac function, reduce hospitalization rates, and enhance quality of life in patients with chronic heart failure. By targeting complementary pathways involved in heart failure, it addresses the underlying neurohormonal imbalances that contribute to disease progression. This 24 mg+26 mg dose is typically used as a starting dose, particularly in patients who are naïve to ACE inhibitors or ARBs or require low-dose initiation due to renal impairment or hypotension.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

Each tablet contains:

• Sacubitril 24 mg

• Valsartan 26 mg

• Excipients: Microcrystalline cellulose, lactose, magnesium stearate, and other standard excipients

Indications

Sacuva Tablet 24 mg+26 mg is indicated for:

• Chronic heart failure with reduced ejection fraction (HFrEF) to reduce morbidity and mortality

• Improvement of symptoms such as fatigue, shortness of breath, and fluid retention

• Reduction of hospitalization rates due to heart failure exacerbations

• Patients requiring a low-dose initiation of Sacubitril/Valsartan therapy due to hypotension, renal impairment, or prior intolerance to ACE inhibitors/ARBs

Mechanism of Action

Sacuva combines two mechanisms for optimal cardiovascular benefit:

1. Sacubitril (Neprilysin inhibitor):

   • Inhibits neprilysin, an enzyme responsible for degrading natriuretic peptides

   • Increases levels of atrial and B-type natriuretic peptides, which promote vasodilation, sodium excretion, and diuresis

   • Reduces cardiac remodeling and fibrosis, improving cardiac function

2. Valsartan (Angiotensin II receptor blocker):

   • Blocks angiotensin II type 1 receptors, reducing vasoconstriction, aldosterone release, and sodium retention

   • Lowers blood pressure and decreases cardiac workload

   • Complements Sacubitril by mitigating neurohormonal overactivation in heart failure

The combination results in enhanced natriuresis, vasodilation, and reduced cardiac stress, improving patient outcomes and survival in HFrEF.

Dosage and Administration

• Adults: 1 tablet once or twice daily, as prescribed by the physician

• Tablets should be taken with or without food, at the same time each day

• For patients not previously on ACE inhibitors, a washout period of 36 hours is required before starting therapy

• Regular monitoring of blood pressure, kidney function, and electrolytes is recommended

• Dose may be titrated upward based on tolerability and clinical response

Precautions and Warnings

• Not recommended during pregnancy due to risk of fetal toxicity

• Avoid concomitant use with ACE inhibitors or aliskiren in patients with diabetes or renal impairment

• Monitor for hypotension, hyperkalemia, and renal function deterioration

• Use caution in patients with a history of angioedema or severe liver disease

• Seek immediate medical attention if severe dizziness, swelling of the face or throat, or difficulty breathing occurs

Possible Side Effects

Sacuva Tablet 24 mg+26 mg is generally well tolerated. Common side effects may include:

• Dizziness or lightheadedness

• Hypotension (low blood pressure)

• Hyperkalemia (elevated potassium levels)

• Mild kidney function alterations

• Rarely, angioedema

Most adverse effects are mild and manageable with dose adjustments under physician supervision.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Storage Instructions

• Store in a cool, dry place below 30°C

• Protect from light and moisture

• Keep out of reach of children

Conclusion

Sacuva Tablet 24 mg+26 mg (Sacubitril + Valsartan) is an effective starting-dose therapy for heart failure with reduced ejection fraction. Its dual action improves cardiac function, reduces hospitalization, and enhances quality of life. Proper initiation and monitoring, combined with lifestyle and guideline-directed therapy, make Sacuva a cornerstone in the management of HFrEF.